Results:
Forty-seven patients {27 with central nervous system(CNS) and 20 with
non-CNS tumors} with a median age of 9years were evaluated. Most common
diagnoses were ependymoma, rhabdomyosarcoma and glioma. Median dose
delivered was 54.8CGE(40-70.4) to a median clinical target volume of
175cc (18.7-3083cc) with 34% requiring concurrent chemotherapy(CCT).
Acute grade-2 and 3 dermatitis, mucositis, and hematological toxicity
was noted in 45% and 2%; 34% and 0%; 38% and 30%; respectively.
Grade-2 fatigue was noted in 26%. On univariate analysis, CCT(p=0.009)
and cranio-spinal irradiation(p<0.001) were associated with
grade-2 or more hematological toxicityin patients with CNS tumors. Among
non-CNS tumors, clinical target volume more than 150cc was associated
with grade-2 or more fatigue(p=0.017).